CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy
- 1Department of Laboratory Medicine, The People’s Hospital of Qiannan, Duyun, Guizhou, China
- 2Department of Dermatology, The People’s Hospital of Qiannan, Duyun, Guizhou, China
Abstract
Malignant melanoma (MM) is a highly aggressive malignancy that readily metastasizes to lymph nodes and distant sites through hematogenous spread, leading to poor clinical outcomes. Therefore, there is an urgent need to develop novel therapeutic strategies. Chondroitin sulfate proteoglycan 4 (CSPG4) is one of the most frequently overexpressed proteins on malignant melanoma cells, whereas it is only expressed at very low levels in normal tissues. In this study, a novel bispecific T‑cell engager, CD3‑CSPG4/BiTE, was constructed by linking single‑chain antibodies directed against CSPG4 and CD3. In vitro assays assessed its simultaneous and specific binding to CSPG4 ⁺ melanoma cells and T cells, its capacity to drive T-cell proliferation and activation, and its ability to redirect T-cell cytotoxicity toward CSPG4 ⁺ targets. Additionally, in NOD/SCID mice bearing established human melanoma xenografts, the antitumor efficacy and systemic toxicity of the molecule were evaluated. CD3-CSPG4/BiTE was successfully generated and was shown to simultaneously bind CSPG4 ⁺ melanoma cells and T cells. Flow-cytometric analysis revealed that, compared with control constructs, CD3-CSPG4/BiTE markedly enhanced T-cell proliferation and activation (as evidenced by up-regulated CD25 and CD69) and effectively redirected T-cell–mediated lysis of CSPG4 ⁺ targets in vitro. In NOD/SCID mice bearing human melanoma xenografts, the BiTE significantly suppressed tumor growth without eliciting detectable toxicity in major organs. In summary, this study successfully developed a novel bispecific T-cell engager, CD3-CSPG4/BiTE, and demonstrated its potent antitumor activity against malignant melanoma both in vitro and in vivo. These findings provide a preclinical foundation for the clinical translation and further optimization of BiTE-based immunotherapy for melanoma.
Related
- 902 Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy
- 1054 Pharmaceutical surgery by design: IV dosed virus ATTR02 enables in-tumor production of a universal bispecific T cell engager to address tumor heterogeneity
- 825 Intratumoral B7H3:CD3 bispecific T-cell engager drives localized T-cell accumulation in canine sarcoma patients
- Bispecific VSV-G Engagers: A Platform for Cell-Type-Specific Delivery of Viral Vectors
- 627 An innovative approach to improve bispecific T-cell engagers for solid tumor therapy
BibTeX
@article{lei2026cd3cspg4,
title = {{CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy}},
author = {Xue Lei and Weilan Liu and Zongnian Luo and Bangyong Wu and Yu Meng and Qiang Jiang},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0357790},
url = {https://doi.org/10.1371/journal.pone.0357790},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy
AU - Xue Lei
AU - Weilan Liu
AU - Zongnian Luo
AU - Bangyong Wu
AU - Yu Meng
AU - Qiang Jiang
PY - 2026
DA - 2026/10/05
JO - PLOS One
DO - 10.1371/journal.pone.0357790
UR - https://doi.org/10.1371/journal.pone.0357790
AB - Malignant melanoma (MM) is a highly aggressive malignancy that readily metastasizes to lymph nodes and distant sites through hematogenous spread, leading to poor clinical outcomes. Therefore, there is an urgent need to develop novel therapeutic strategies. Chondroitin sulfate proteoglycan 4 (CSPG4) is one of the most frequently overexpressed proteins on malignant melanoma cells, whereas it is only expressed at very low levels in normal tissues. In this study, a novel bispecific T‑cell engager, CD3‑CSPG4/BiTE, was constructed by linking single‑chain antibodies directed against CSPG4 and CD3. In vitro assays assessed its simultaneous and specific binding to CSPG4 ⁺ melanoma cells and T cells, its capacity to drive T-cell proliferation and activation, and its ability to redirect T-cell cytotoxicity toward CSPG4 ⁺ targets. Additionally, in NOD/SCID mice bearing established human melanoma xenografts, the antitumor efficacy and systemic toxicity of the molecule were evaluated. CD3-CSPG4/BiTE was successfully generated and was shown to simultaneously bind CSPG4 ⁺ melanoma cells and T cells. Flow-cytometric analysis revealed that, compared with control constructs, CD3-CSPG4/BiTE markedly enhanced T-cell proliferation and activation (as evidenced by up-regulated CD25 and CD69) and effectively redirected T-cell–mediated lysis of CSPG4 ⁺ targets in vitro. In NOD/SCID mice bearing human melanoma xenografts, the BiTE significantly suppressed tumor growth without eliciting detectable toxicity in major organs. In summary, this study successfully developed a novel bispecific T-cell engager, CD3-CSPG4/BiTE, and demonstrated its potent antitumor activity against malignant melanoma both in vitro and in vivo. These findings provide a preclinical foundation for the clinical translation and further optimization of BiTE-based immunotherapy for melanoma.
SN - 1932-6203
ER -